USFDA conducted an inspection at Zydus Lifesciences Limited's manufacturing facility SEZ-1 at Pharmez, Ahmedabad from March 20 to March 24, 2023, the company announced through an exchange filing. The inspection was a pre-approval inspection (PAI) and a GMP Audit that concluded with three observations.
The company said that there were no data integrity related observations and the company is addressing these observations.
Zydus received final approval from USFDA for Lubiprostone Capsules, the company announced on March 24.
Zydus Lifesciences shares
YouTube To Pay USD 24.5 Million To Settle 2021 Lawsuit By US President Donald Trump Over Account Suspension
Game Of Glory OTT Release Date: When & Where To Watch Abhishek Malhan's Latest Show Online
Here's How A 4-Year-Old Girl In China Survived 20th-Floor Fall After Landing On Rain Canopy
'We Must Be Prepared': CDS General Anil Chauhan Calls For Preparedness Against Bio-Threats & Radio Contamination - Videos
The shares of Zydus Lifesciences on Friday closed at Rs 480.05, down by 0.47 per cent.
